Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial

ESMO Gastrointestinal Oncology 2026 Open access

Read full text
Authors: Ramona Stelmach, S. Lorenzen, T.J. Ettrich, F.R. Longo, Benoist Chibaudel, R. Greil, M. Perwög, J. Larcher-Steiner, D. Jäger, Florian Lordick, Gertraud Stocker, G.M. Haag
DOI: 10.1016/j.esmogo.2025.100297
Cited by: 0
References: 19

Abstract

Background Malnutrition is common in patients with metastatic esophagogastric adenocarcinoma (EGA). However, the prognostic impact of nutritional risk screening (NRS) in advanced EGA remains underexplored. This preplanned analysis of the phase II AIO-MATEO trial evaluated the impact of NRS on clinical outcomes for patients with advanced EGA. Patients and methods Patients enrolled in the MATEO trial (exploring S-1 maintenance therapy) with an available baseline NRS before induction chemotherapy were included. Patients were stratified by their baseline NRS score (

Fields of Study & Subjects

Gastric Cancer Management and Outcomes Nutrition and Health in Aging Esophageal Cancer Research and Treatment

Publication details

Journal / source
ESMO Gastrointestinal Oncology
Volume
11
Pages
100297–100297
Publication date
27 January 2026
Language
EN